TK1 and lung cancer: We propose that STK1p should be combined with imaging, other biomarkers (e.g., CYFRA21-1, CEA and CTCs) and TK1 immunohistochemically staining, to provide a reliable method for assessment of the development of premalignancy or diseases associated with the risk process of lung cancer.